41. Which of the following statements is true concerning a product that has a Risk Evaluation and Mitigation Strategy (REMS) program?
Answer: D
The product would not be on the market without a REMS program due to patient safety concerns.
A product with a Risk Evaluation and Mitigation Strategy (REMS) program is required to ensure that its benefits outweigh its risks. This regulatory measure is crucial for maintaining patient safety, suggesting that the product would not be available to the public without such safeguards in place.
A) Compounding the product must be done according to instructions found in the REMS program
This statement is incorrect because while REMS programs provide important safety information, they do not specifically mandate compounding instructions. Compounding practices are generally governed by other regulations and standards, not solely by the REMS.
B) A product with a REMS program is more likely to be involved in misuse or diversion
Although products with REMS programs may be subject to higher scrutiny due to their associated risks, this statement is not inherently true. The purpose of a REMS program is to prevent misuse and ensure safe use, rather than indicating a higher likelihood of misuse or diversion.
C) Whether to adhere to the product's REMS program guidelines is determined by pharmacist discretion
This option is misleading because adherence to REMS program guidelines is mandatory and not subject to pharmacist discretion. Pharmacists must follow the established REMS protocols to ensure compliance with regulatory requirements and patient safety.
D) The product would not be on the market without a REMS program due to patient safety concerns
This statement accurately reflects the regulatory requirements surrounding REMS programs. Products with significant safety risks must have a REMS in place to mitigate those risks, ensuring that they can be safely prescribed and used.
Conclusion
The correct answer, D, emphasizes the essential role of REMS programs in protecting patient safety and confirms that such products would not be available without these crucial safeguards. Other options fail to recognize the regulatory framework and purpose of REMS, making them incorrect in this context.